Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC is a phase 3, randomised interventional study registered as NCT05768503 by Sun Yat-sen University, with a registry enrolment figure of 176 participants, started 2023-03-01 and due to reach its primary completion in 2026-01. Interventions recorded: Experimental drug; Control Rx. Conditions listed: Metastatic Microsatellite-stable Colorectal Cancer. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Locally advanced unresectable or metastatic colorectal adenocarcinoma (excluding mixed adenosquamous carcinoma and other pathological types) confirmed by pathological histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.